Ranbaxy Laboratories to market Daiichi Sankyo's Sevikarin in Romania

NEW DELHI: Ranbaxy Laboratories will market Daiichi Sankyo's antihypertensive drug Sevikarin in Romania expanding its hybrid model strategy to the European country.

The Indian company will sell Sevikar, a combination of amlodipine besylate and olmesartan medoxomil, in three dosages Ranbaxy said in a release.

Ranbaxy CEO & MD Arun Sawhney said, “Leveraging synergies with Daiichi Sankyo is part of our business strategy and this will be our third product introduction as part of the hybrid business model.”

Sevikar is a once-daily, single pill fixed dose combination (FDC) discovered by Daiichi Sankyo. The pharmaceutical market in Romania is valued at about $3.3 billion with cardiovascular segment being a major contributor with sales of $271 million in 2011.

Ranbaxy's share price is trading at Rs 518.20, up 1.91% at the BSE.

In 2008, Japan's Daiichi Sankyo bought 64% in the country's largest drug maker. It has gradually started using Ranbaxy's globally marketing network to expand its original products to newer geographies. Ranbaxy is a generic drug company.